FIGURE 7 from Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts
Year: 2024
Type: other
Abstract: Synergy between TAK-243 and Venetoclax in organoids generated from patient-derived xenograft (PDXO). A, Representative brightfield images of PDXOs (20x magnification, scale bar 50 µm). B, Phenotypic characteristics of PDXOs. Expression of biomarkers routinely used to diagnose ACC, including inhibin-α, SF-1, INSM-1, and β-catenin in ACC-PDX-derived organoids using immunofluorescence assay. C, Top: The indicated ACC PDXOs were treated with TAK-243 with or without Venetoclax for 72 hours. Bottom: Plots of the corresponding CI values.
Authors: Yasuhiro Arakawa, Ukhyun Jo, Suresh Kumar, Nai-Yun Sun, Fathi Elloumi, Anish Thomas, Nitin Roper, Diana Grace Varghese, Naoko Takebe, Xiaohu Zhang, Michele Ceribelli, David O. Holland, Erin Beck, Zina Itkin, Crystal McKnight, Kelli M. Wilson, Jameson Travers, Carleen Klumpp-Thomas, Craig J. Thomas, Chuong D. Hoang, Jonathan M. Hernandez, Jaydira Del Rivero, Yves Pommier
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4392951866